00:29 , Dec 9, 2017 |  BioCentury  |  Strategy

Genmab’s second act

For the second time, Genmab A/S finds itself at the threshold of transitioning into a commercial biotech and is planning to change its partnering approach to retain a more significant portion of the value of...
07:00 , Jul 9, 2015 |  BC Innovations  |  Strategy

The priority of proximity

Following on two years of success with its four innovation centers, Johnson & Johnson is expanding its hub-and-spoke model for identifying and developing external early stage innovations to new regions. Among the 17 deals announced...
07:00 , Jun 1, 2015 |  BioCentury  |  Finance

Third Rock settles for an A

Third Rock Ventures says its absence from recent series B rounds in companies it founded reflects a confluence of its focus on company building from the ground up and the desire of crossover investors to...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
07:00 , Apr 27, 2015 |  BioCentury  |  Finance

Killer Bs

Massive financings for Dimension Therapeutics Inc. and Jounce Therapeutics Inc. have pushed the average size of a series B round this year north of $31 million. The figure is roughly on par with the 2014...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Sticking it to sickle cell

Global Blood Therapeutics Inc. raised $48 million in a series B round that will enable the company to reach clinical proof of concept for its lead sickle cell disease program in mid-2015, after which CEO...
07:00 , Sep 22, 2014 |  BioCentury  |  Finance

Polar (large) caps

With one fund already focused on large cap pharma, Polar Capital has launched a new fund - with the backing of a happy client - to expand the large cap-focused strategy to encapsulate other healthcare...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Polar Capital Holdings plc financial update

Last year Polar started fund raising, with a $500 million capacity, for its Biotechnology Fund focused across all therapeutic areas, stages of development and market caps (see BioCentury, Nov. 4, 2013). Polar Capital Holdings plc...
01:33 , Sep 13, 2014 |  BC Extra  |  Financial News

Polar Capital raising large cap biotech fund

Polar Capital is fundraising for an open-ended global biotech fund focused on large cap companies. The Polar Capital Healthcare Blue Chip Fund will be managed by Gareth Powell and Daniel Mahony, who have both been...
01:55 , Dec 5, 2013 |  BC Extra  |  Financial News

Obesity play Zafgen secures $45 million in series E

Zafgen Inc. (Cambridge, Mass.) raised $35 million in the first tranche of a $45 million series E round from new investors RA Capital Management; Brookside Capital; Venrock; an undisclosed blue chip investor; and a private...